Tackling the Rising Costs of Specialty Drugs

Specialty drugs account for just 1–2% of prescriptions but drive over 50% of total healthcare spend — and costs are climbing every year. In this episode of Boss Moves in Benefits, Ken Bahl sits down with Robin Bahl, CEO of Custom Benefit Consultants, along with Kristin Gray Hamilton and Jonathan Harvin from Navitus, to unpack what’s driving these skyrocketing costs and, more importantly, how to manage them. From understanding what qualifies as a specialty drug, to exploring transparent PBM models, biosimilars, and medical vs. pharmacy benefit strategies, this conversation dives deep into practical, proven approaches that lower costs while protecting outcomes. Whether you’re a consultant, employer, or benefits leader, this episode equips you with the insights you need to navigate the specialty drug challenge with confidence.